SHR-1701 for Consolidation Therapy After Concurrent Chemoradiotherapy in Inoperable Stage III NSCLC
Status:
Not yet recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
This is a phase II, open-label, single arm study, aiming to investigate the safety and
efficacy of SHR-1701 consolidation therapy after concurrent chemoradiotherapy in inoperable
stage III non-small-cell lung cancer (NSCLC)